OBJECTIVES: Triple negative breast cancer (TNBC), characterized by lack of estrogen and progesterone receptors, and HER2 not being over-expressed, does not respond to standard therapies, and exhibits more aggressive clinical behavior. The objective of this study was to assess the clinical outcomes of TNBC patients compared to other types of BC in a US local community practice. METHODS: A retrospective analysis was conducted using the Georgia Cancer Specialist Database (2003-2008).  Patients with BC and confirmed TN/non-TN status were selected. For stage I-III patients, the outcomes were disease-free survival (DFS) and recurrence.  For stage IV patients, the outcome was overall survival (OS).  Kaplan-Meier curves were used to compare the event rates between TN and non-TN groups.  The impact of TN status on the outcomes was examined with multivariate Cox models adjusting for demographic and clinical characteristics. RESULTS: There were 1572 stage I-III patients with 26.3% (n=414) being TN and 245 stage IV with 25.7% (n=63) TN. For stage I-III, TN group had significantly lower rate for 5-year DFS (76.8% vs. 89.0%) and higher rate for 5-year recurrence (18.8% vs. 11.2%), compared to non-TN group (all p<0.001).  The adjusted results demonstrated significant association between TN status and lower likelihood of DFS (HR=0.37) and higher risk for recurrence (HR=2.85), both p<0.0001. For stage IV, TN group was found to have significantly shorter Median OS (405 vs. 847 days, P= 0.0003).  The adjusted results showed TN status was associated with high risk of mortality (HR=2.20, p=0.0004). CONCLUSIONS: Based on data from a US local oncology practice, this study demonstrated inferior clinical outcomes for TNBC compared to other types of BC. The results highlight the need for better understanding and more effective treatments for TN subtype. The results could be confounded by uncontrolled factors and need to be confirmed in other oncology practices.